Chronic obstructive pulmonary disease Trials in Katowice, Poland
Conditions / Chronic obstructive pulmonary disease / Katowice, Poland
Research into Chronic obstructive pulmonary disease spans multiple therapeutic approaches and trial phases.
18 total trials for this combination
Showing top 10 of 18 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04636801 | A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) | TERMINATED | PHASE3 |
| NCT00845728 | Exacerbation Study | COMPLETED | PHASE3 |
| NCT04636814 | A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) | TERMINATED | PHASE3 |
| NCT01120691 | Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations | COMPLETED | PHASE3 |
| NCT02796677 | AMPLIFY - D6571C00001 Duaklir USA Phase III Study | COMPLETED | PHASE3 |
| NCT03930732 | Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation | COMPLETED | PHASE3 |
| NCT04456673 | Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation | COMPLETED | PHASE3 |
| NCT05878769 | A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | RECRUITING | PHASE3 |
| NCT04053634 | Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations | COMPLETED | PHASE3 |
| NCT04751487 | Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | — |